The Histone demethylase PHF8 governs retinoic acid response in acute promyelocytic leukemia

Cancer Cell

Volumn 23, Issue 3, 2013, Pages 376-389

  Arteaga, Maria Francisca ^a   Mikesch, Jan Henrik ^a   Qiu, Jihui ^b   Christensen, Jesper ^c,d   Helin, Kristian ^c,d,e   Kogan, Scott C ^f   Dong, Shuo ^b   So, Chi Wai Eric ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e University of Copenhagen   (Denmark)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEMETHYLASE; PHF8 PROTEIN; PROTEIN; RAR ALPHA; RETINOIC ACID; SERINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER RESISTANCE; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; DRUG RESPONSE; ENZYME ACTIVITY; HISTONE MODIFICATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; TRANSACTIVATION;

EID: 84876443700     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.02.014     Document Type: Article

References (49)

1. Abidi F.E., Miano M.G., Murray J.C., Schwartz C.E. A novel mutation in the PHF8 gene is associated with X-linked mental retardation with cleft lip/cleft palate. Clin. Genet. 2007, 72:19-22.
2. Arrowsmith C.H., Bountra C., Fish P.V., Lee K., Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov. 2012, 11:384-400.
3. Boukarabila H., Saurin A.J., Batsché E., Mossadegh N., van Lohuizen M., Otte A.P., Pradel J., Muchardt C., Sieweke M., Duprez E. The PRC1 Polycomb group complex interacts with PLZF/RARA to mediate leukemic transformation. Genes Dev. 2009, 23:1195-1206.
4. Cheung N., So C.W. Transcriptional and epigenetic networks in haematological malignancy. FEBS Lett. 2011, 585:2100-2111.
5. Côté S., Zhou D., Bianchini A., Nervi C., Gallagher R.E., Miller W.H. Altered ligand binding and transcriptional regulation by mutations in the PML/RARalpha ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia. Blood 2000, 96:3200-3208.
6. de Thé H., Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat. Rev. Cancer 2010, 10:775-783.
7. Ekberg J., Landberg G., Holm C., Richter J., Wolgemuth D.J., Persson J.L. Regulation of the cyclin A1 protein is associated with its differential subcellular localization in hematopoietic and leukemic cells. Oncogene 2004, 23:9082-9089.
8. Epping M.T., Wang L., Edel M.J., Carlée L., Hernandez M., Bernards R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 2005, 122:835-847.
9. Feng W., Yonezawa M., Ye J., Jenuwein T., Grummt I. PHF8 activates transcription of rRNA genes through H3K4me3 binding and H3K9me1/2 demethylation. Nat. Struct. Mol. Biol. 2010, 17:445-450.
10. Fortschegger K., de Graaf P., Outchkourov N.S., van Schaik F.M., Timmers H.T., Shiekhattar R. PHF8 targets histone methylation and RNA polymerase II to activate transcription. Mol. Cell. Biol. 2010, 30:3286-3298.
11. Grignani F., De Matteis S., Nervi C., Tomassoni L., Gelmetti V., Cioce M., Fanelli M., Ruthardt M., Ferrara F.F., Zamir I., et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 1998, 391:815-818.
12. Gronemeyer H., Gustafsson J.A., Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat. Rev. Drug Discov. 2004, 3:950-964.
13. Guidez F., Parks S., Wong H., Jovanovic J.V., Mays A., Gilkes A.F., Mills K.I., Guillemin M.C., Hobbs R.M., Pandolfi P.P., et al. RARalpha-PLZF overcomes PLZF-mediated repression of CRABPI, contributing to retinoid resistance in t(11;17) acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 2007, 104:18694-18699.
14. He L.Z., Guidez F., Tribioli C., Peruzzi D., Ruthardt M., Zelent A., Pandolfi P.P. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat. Genet. 1998, 18:126-135.
15. Hölzel M., Huang S., Koster J., Ora I., Lakeman A., Caron H., Nijkamp W., Xie J., Callens T., Asgharzadeh S., et al. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 2010, 142:218-229.
16. Huang S., Laoukili J., Epping M.T., Koster J., Hölzel M., Westerman B.A., Nijkamp W., Hata A., Asgharzadeh S., Seeger R.C., et al. ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. Cancer Cell 2009, 15:328-340.
17. Kleine-Kohlbrecher D., Christensen J., Vandamme J., Abarrategui I., Bak M., Tommerup N., Shi X., Gozani O., Rappsilber J., Salcini A.E., Helin K. A functional link between the histone demethylase PHF8 and the transcription factor ZNF711 in X-linked mental retardation. Mol. Cell 2010, 38:165-178.
18. Kogan S.C., Hong S.H., Shultz D.B., Privalsky M.L., Bishop J.M. Leukemia initiated by PMLRARalpha: the PML domain plays a critical role while retinoic acid-mediated transactivation is dispensable. Blood 2000, 95:1541-1550.
19. Koivisto A.M., Ala-Mello S., Lemmelä S., Komu H.A., Rautio J., Järvelä I. Screening of mutations in the PHF8 gene and identification of a novel mutation in a Finnish family with XLMR and cleft lip/cleft palate. Clin. Genet. 2007, 72:145-149.
20. Kooistra S.M., Helin K. Molecular mechanisms and potential functions of histone demethylases. Nat. Rev. Mol. Cell Biol. 2012, 13:297-311.
21. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128:693-705.
22. Kwok C., Zeisig B.B., Dong S., So C.W. Forced homo-oligomerization of RARalpha leads to transformation of primary hematopoietic cells. Cancer Cell 2006, 9:95-108.
23. Laumonnier F., Holbert S., Ronce N., Faravelli F., Lenzner S., Schwartz C.E., Lespinasse J., Van Esch H., Lacombe D., Goizet C., et al. Mutations in PHF8 are associated with X linked mental retardation and cleft lip/cleft palate. J. Med. Genet. 2005, 42:780-786.
24. Lin R.J., Evans R.M. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol. Cell 2000, 5:821-830.
25. Lin R.J., Nagy L., Inoue S., Shao W., Miller W.H., Evans R.M. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998, 391:811-814.
26. Liu W., Tanasa B., Tyurina O.V., Zhou T.Y., Gassmann R., Liu W.T., Ohgi K.A., Benner C., Garcia-Bassets I., Aggarwal A.K., et al. PHF8 mediates histone H4 lysine 20 demethylation events involved in cell cycle progression. Nature 2010, 466:508-512.
27. Loenarz C., Ge W., Coleman M.L., Rose N.R., Cooper C.D., Klose R.J., Ratcliffe P.J., Schofield C.J. PHF8, a gene associated with cleft lip/palate and mental retardation, encodes for an Nepsilon-dimethyl lysine demethylase. Hum. Mol. Genet. 2010, 19:217-222.
28. Martens J.H., Brinkman A.B., Simmer F., Francoijs K.J., Nebbioso A., Ferrara F., Altucci L., Stunnenberg H.G. PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. Cancer Cell 2010, 17:173-185.
29. Matthay K.K., Reynolds C.P., Seeger R.C., Shimada H., Adkins E.S., Haas-Kogan D., Gerbing R.B., London W.B., Villablanca J.G. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J. Clin. Oncol. 2009, 27:1007-1013.
30. McNamara S., Wang H., Hanna N., Miller W.H. Topoisomerase IIbeta negatively modulates retinoic acid receptor alpha function: a novel mechanism of retinoic acid resistance. Mol. Cell. Biol. 2008, 28:2066-2077.
31. Mikesch J.H., Gronemeyer H., So C.W. Discovery of novel transcriptional and epigenetic targets in APL by global ChIP analyses: Emerging opportunity and challenge. Cancer Cell 2010, 17:112-114.
32. Minucci S., Maccarana M., Cioce M., De Luca P., Gelmetti V., Segalla S., Di Croce L., Giavara S., Matteucci C., Gobbi A., et al. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol. Cell 2000, 5:811-820.
33. Qi H.H., Sarkissian M., Hu G.Q., Wang Z., Bhattacharjee A., Gordon D.B., Gonzales M., Lan F., Ongusaha P.P., Huarte M., et al. Histone H4K20/H3K9 demethylase PHF8 regulates zebrafish brain and craniofacial development. Nature 2010, 466:503-507.
34. Qiu J., Shi G., Jia Y., Li J., Wu M., Li J., Dong S., Wong J. The X-linked mental retardation gene PHF8 is a histone demethylase involved in neuronal differentiation. Cell Res. 2010, 20:908-918.
35. Roussel M.J., Lanotte M. Maturation sensitive and resistant t(15;17) NB4 cell lines as tools for APL physiopathology: nomenclature of cells and repertory of their known genetic alterations and phenotypes. Oncogene 2001, 20:7287-7291.
36. Sanz M.A., Lo-Coco F. Modern approaches to treating acute promyelocytic leukemia. J. Clin. Oncol. 2011, 29:495-503.
37. Schenk T., Chen W.C., Göllner S., Howell L., Jin L., Hebestreit K., Klein H.U., Popescu A.C., Burnett A., Mills K., et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat. Med. 2012, 18:605-611.
38. Shultz L.D., Lyons B.L., Burzenski L.M., Gott B., Chen X., Chaleff S., Kotb M., Gillies S.D., King M., Mangada J., et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. 2005, 174:6477-6489.
39. Smith L.L., Yeung J., Zeisig B.B., Popov N., Huijbers I., Barnes J., Wilson A.J., Taskesen E., Delwel R., Gil J., et al. Functional crosstalk between Bmi1 and MLL/Hoxa9 axis in establishment of normal hematopoietic and leukemic stem cells. Cell Stem Cell 2011, 8:649-662.
40. Sternsdorf T., Phan V.T., Maunakea M.L., Ocampo C.B., Sohal J., Silletto A., Galimi F., Le Beau M.M., Evans R.M., Kogan S.C. Forced retinoic acid receptor alpha homodimers prime mice for APL-like leukemia. Cancer Cell 2006, 9:81-94.
41. Villa R., Pasini D., Gutierrez A., Morey L., Occhionorelli M., Viré E., Nomdedeu J.F., Jenuwein T., Pelicci P.G., Minucci S., et al. Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell 2007, 11:513-525.
42. Wang Z.Y., Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008, 111:2505-2515.
43. Wang K., Wang P., Shi J., Zhu X., He M., Jia X., Yang X., Qiu F., Jin W., Qian M., et al. PML/RARalpha targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia. Cancer Cell 2010, 17:186-197.
44. Yeung J., So C.W. Identification and characterization of hematopoietic stem and progenitor cell populations in mouse bone marrow by flow cytometry. Methods Mol. Biol. 2009, 538:301-315.
45. Yeung J., Esposito M.T., Gandillet A., Zeisig B.B., Griessinger E., Bonnet D., So C.W. β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell 2010, 18:606-618.
46. Zeisig B.B., So C.W. Retroviral/Lentiviral transduction and transformation assay. Methods Mol. Biol. 2009, 538:207-229.
47. Zeisig B.B., Kwok C., Zelent A., Shankaranarayanan P., Gronemeyer H., Dong S., So C.W. Recruitment of RXR by homotetrameric RARalpha fusion proteins is essential for transformation. Cancer Cell 2007, 12:36-51.
48. Zeisig B.B., Kulasekararaj A.G., Mufti G.J., So C.W. Acute Myeloid Leukemia: Snapshot. Cancer Cell 2012, 22:698.
49. Zhu J., Nasr R., Pérès L., Riaucoux-Lormière F., Honoré N., Berthier C., Kamashev D., Zhou J., Vitoux D., Lavau C., de Thé H. RXR is an essential component of the oncogenic PML/RARA complex in vivo. Cancer Cell 2007, 12:23-35.